Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Top Cited Papers
Open Access
- 26 March 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 125 (13), 2062-2067
- https://doi.org/10.1182/blood-2014-09-603670
Abstract
Key Points Clinical characteristics, causes of discontinuation, and outcome of patients who progress or fail ibrutinib are described. Patients with CLL who progress early on ibrutinib therapy have poor outcomes.This publication has 11 references indexed in Scilit:
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyThe Lancet Oncology, 2014
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2014
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor IbrutinibThe New England Journal of Medicine, 2014
- Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease.Journal of Clinical Oncology, 2014
- Targeting Bruton's tyrosine kinase in B cell malignanciesNature Reviews Cancer, 2014
- Value of the peripheral blood film: megakaryocytic fragments misidentified by automated counterBlood, 2013
- Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialThe Lancet Oncology, 2013
- The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension StudyBlood, 2013
- B-cell receptor signaling as a driver of lymphoma development and evolutionSeminars in Cancer Biology, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013